TCGA-A2-A0T3-01A-21R-A115-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.530
- MYC_TARGETS_V2+0.420
- MITOTIC_SPINDLE+0.390
- PROTEIN_SECRETION+0.370
- MYC_TARGETS_V1+0.310
- ESTROGEN_RESPONSE_EARLY+0.290
- TGF_BETA_SIGNALING+0.280
- UNFOLDED_PROTEIN_RESPONSE+0.280
- ESTROGEN_RESPONSE_LATE+0.260
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.430
- INTERFERON_GAMMA_RESPONSE-0.430
- INFLAMMATORY_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- COMPLEMENT-0.280
- BILE_ACID_METABOLISM-0.270
- IL6_JAK_STAT3_SIGNALING-0.270
- KRAS_SIGNALING_UP-0.250
- APOPTOSIS-0.220
- COAGULATION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07L-01A-11R-A00Z-07 | — | B | 0.885 |
| 2 | SRR23303764 | — | — | 0.862 |
| 3 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.856 |
| 4 | MDT-AP-0540 | Med | Medulloblastoma | 0.854 |
| 5 | BS_MDBT7S5Z | high-grade glioma | — | 0.849 |
| 6 | dd629237-9358-4b4d-bbf2-346e3d5c34be | — | — | 0.848 |
| 7 | SRR25617863 | — | B | 0.843 |
| 8 | TCGA-E2-A154-01A-11R-A115-07 | — | B | 0.843 |
| 9 | TCGA-A2-A04R-01A-41R-A109-07 | — | B | 0.842 |
| 10 | CB9E4206-E2F7-49EA-8FB2-E69E5BB3B018 | — | — | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.260 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.030 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |